Can you provide the average price target for OPKO HEALTH INC stock?
11 analysts have analysed OPK and the average price target is 3.47 USD. This implies a price increase of 191.43% is expected in the next year compared to the current price of 1.19.
NASDAQ:OPK • US68375N1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OPKO HEALTH INC (OPK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-11-20 | JP Morgan | Initiate | Neutral |
| 2025-10-31 | Jefferies | Downgrade | Buy -> Hold |
| 2025-10-30 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-05-01 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-04-25 | JP Morgan | Initiate | Neutral |
| 2025-04-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-28 | Barrington Research | Maintains | Outperform -> Outperform |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-09-17 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-08 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-07-18 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-05-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-01 | Barrington Research | Maintains | Outperform -> Outperform |
| 2024-04-01 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-02-28 | Barrington Research | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 863.495M -14.01% | 713.142M -17.41% | 606.879M -14.90% | 556.73M -8.26% | 580.33M 4.24% | 614.18M 5.83% | 654.73M 6.60% | 695.23M 6.19% | 695.18M -0.01% | 723.67M 4.10% | 753.97M 4.19% | |
| EBITDA YoY % growth | -51.724M 62.02% | -175.382M -239.07% | -127.358M 27.38% | -82.063M 35.57% | -13.08M 84.06% | 52.554M 501.80% | 95.849M 82.38% | 146.45M 52.79% | 177.26M 21.04% | 198.97M 12.25% | 211.09M 6.09% | |
| EBIT YoY % growth | -157.021M 35.88% | -273.558M -74.22% | -218.985M 19.95% | -187.216M 14.51% | -172.569M 7.82% | -42.083M 75.61% | 13.736M 132.64% | 60.802M 342.65% | 87.87M 44.52% | 105.95M 20.58% | 114.13M 7.72% | |
| Operating Margin | -18.18% | -38.36% | -36.08% | -33.63% | -29.74% | -6.85% | 2.10% | 8.75% | 12.64% | 14.64% | 15.14% | |
| EPS YoY % growth | -0.25 44.07% | -0.21 14.66% | -0.30 -42.86% | -0.27 8.62% | -0.24 12.81% | -0.08 68.31% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.07 29.30% | -0.07 62.79% | -0.07 -340.48% | -0.08 -91.17% | -0.07 | -0.07 | -0.07 6.66% | -0.07 11.94% |
| Revenue Q2Q % growth | 131.82M -12.06% | 137.69M -12.19% | 139.09M -8.31% | 143.07M -3.66% | 140.59M 6.65% | 147.53M 7.15% | 146.08M 5.03% | 153.35M 7.19% |
| EBITDA Q2Q % growth | -31.108M 28.78% | -32.286M -139.74% | -29.963M -290.44% | -30.031M -156.33% | -15.655M 49.68% | -14.544M 54.95% | -11.615M 61.24% | -10.302M 65.70% |
| EBIT Q2Q % growth | -47.649M 29.06% | -47.719M 20.44% | -47.741M 10.80% | -49.042M -27.99% | -52.116M -9.38% | -51.106M -7.10% | -49.591M -3.87% | -51.611M -5.24% |
All data in USD
11 analysts have analysed OPK and the average price target is 3.47 USD. This implies a price increase of 191.43% is expected in the next year compared to the current price of 1.19.
OPKO HEALTH INC (OPK) will report earnings on 2026-04-28.
The consensus EPS estimate for the next earnings of OPKO HEALTH INC (OPK) is -0.07 USD and the consensus revenue estimate is 131.82M USD.
The expected long term growth rate for OPKO HEALTH INC (OPK) is 0.55%.